FUJIFILM Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery through to commercialization, today announced new names and identities as part of a strategic positioning effort.

富士胶片公司生命科学集团旗下的企业，涵盖从药物发现到商业化的各个阶段，提供产品、服务和综合解决方案。今天，作为战略定位努力的一部分，该集团宣布了新的名称和身份。

The Group Companies’ new names, collaborative strategic focus, and structural alignment reflects Fujifilm’s commitment to Life Sciences, offering fully integrated, end-to-end solutions across the drug development lifecycle—from research and discovery to clinical and commercial manufacturing..

集团公司的新名称、协作战略重点和结构整合反映了富士胶片对生命科学的承诺，提供贯穿药物开发生命周期的完全集成端到端解决方案——从研究发现到临床和商业生产。

FUJIFILM Irvine Scientific, headquartered in Santa Ana, California rebrands as FUJIFILM Biosciences under this new structure and strategy. The new name encompasses FUJIFILM Biosciences’ evolution over the past 55 years – from its formation in 1970 to its recent expansion to serve broader life sciences communities and customers.

富士胶片欧文科技公司总部位于加利福尼亚州圣安娜，按照这一新的结构和战略重组为富士胶片生物科学公司。新名称涵盖了富士胶片生物科学公司过去55年的发展历程——从1970年成立到最近扩展以服务更广泛的生命科学领域和客户。

It is also a nod to its scientific roots as a pioneer in the cell culture media industry with a core focus on innovation and quality. Today, FUJIFILM Biosciences offers a comprehensive portfolio of discovery and research reagents, recombinant growth factors and proteins, specialty chemicals, and critical assay materials in addition to its robust cell culture media and supplements solutions in the U.S.*1 The new brand name will take effect immediately, and the legal entity name change will be effective January 1, 2026..

它还体现了其作为细胞培养基行业先驱的科学根基，核心专注于创新和质量。如今，富士胶片生物科学公司在美国提供全面的发现和研究试剂、重组生长因子和蛋白质、特种化学品及关键检测材料组合，*1 除此之外还有强大的细胞培养基和补充剂解决方案。新品牌名称将立即生效，而法律实体名称变更将于2026年1月1日生效。

FUJIFILM Diosynth Biotechnologies, a leading global contract development and manufacturing organization (CDMO), first acquired by the Fujifilm Group in 2011, rebrands to FUJIFILM Biotechnologies. The Company serves its global partners offering capabilities for process development through commercial supply, with world-class manufacturing operations across Europe, and the U.S The Company’s legal name will not change..

富士胶片迪奥斯ynth生物技术公司（FUJIFILM Diosynth Biotechnologies），作为全球领先的合同开发和制造组织（CDMO），于2011年首次被富士胶片集团收购，现更名为富士胶片生物技术公司（FUJIFILM Biotechnologies）。该公司为全球合作伙伴提供从工艺开发到商业供应的能力，并在欧洲和美国拥有世界级的制造业务。公司的法定名称不会更改。

Over the past 15 years, Fujifilm has invested over $10 billion through expansions and acquisitions to build its end-to-end life sciences capabilities to create an accelerated path toward greater patient access for advanced care.

在过去的 15 年里，富士胶片已通过扩建和收购投资了超过 100 亿美元，以打造其端到端的生命科学能力，为先进护理创造一条加速患者获取的途径。

“Under the ‘Partners for Life’ umbrella, our Life Sciences Group companies offer complete solutions to the pharmaceutical and biotechnology markets, aligning with both our strategic growth plans and commitment to innovation,” commented Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation, Japan.

“在‘终身合作伙伴’的旗帜下，我们的生命科学集团企业为制药和生物技术市场提供完整的解决方案，这与我们的战略增长计划和创新承诺保持一致，”富士胶片公司生命科学战略总部及生物CDMO部门总监、公司副总裁Toshihisa Iida评论道。

“By redefining our Life Sciences Group, we also support Fujifilm’s growth strategy for the life sciences sector, where we believe that unifying under a single banner will simplify engagement for our global network of customers across the entire product development and biomanufacturing spectrum. It is an opportunity to ensure the teams in all our Life Sciences companies share the same strategy and strong sense of purpose.

“通过重新定义我们的生命科学集团，我们还支持富士胶片在生命科学领域的发展战略。我们相信，统一在一个旗帜下将简化全球客户在整个产品开发和生物制造领域的合作。这是一个确保我们所有生命科学公司的团队共享相同战略和强烈使命感的机会。”

By combining our proprietary technologies, such as AI and sensing, which have been cultivated in the fields of imaging and healthcare, we create new value and support pharmaceutical companies, biotech firms, and academia in both drug discovery support solutions and CDMO services.”.

通过结合我们在影像和医疗领域培育的专有技术，如人工智能和传感技术，我们创造新的价值，并在药物发现支持解决方案和CDMO服务方面为制药公司、生物技术公司及学术界提供支持。

“FUJIFILM Biosciences focuses on supporting our partners in their life sciences ambitions and doing what we can to enable their success along the way,” said Brandon Pence, president and chief operating officer, FUJIFILM Biosciences. “Our foundation is based upon the core principles of putting our people first, transforming through innovation and science, and maintaining a commitment to unprecedented customer service.

“富士胶片生物科学专注于支持我们的合作伙伴在生命科学领域的雄心壮志，并尽我们所能帮助他们在此过程中取得成功，”富士胶片生物科学总裁兼首席运营官布兰登·彭斯表示。“我们的基础建立在以人为本、通过创新和科学实现转型以及坚持对客户提供无与伦比的服务承诺这些核心原则之上。”

In doing those things right, we create strong relationships, both internally and externally. We’re excited about this evolution in our business and welcome the opportunity to expand our positive impact on customers through broader capabilities and collaborating with them on future solutions.”.

在正确处理这些事情的过程中，我们建立了牢固的内外部关系。我们对业务的这一演变感到兴奋，并欢迎通过更广泛的能力和与客户合作开发未来解决方案来扩大我们对客户的积极影响的机会。

“At FUJIFILM Biotechnologies, we take immense pride in the value we bring to our partners everyday to help bring life-changing medicines to patients,” said Lars Petersen, president and chief executive officer, FUJIFILM Biotechnologies.'This closer coordination and united focus strengthens how we interact and deliver for our customers.

“在富士胶片生物技术公司，我们为每天为合作伙伴带来的价值感到无比自豪，这有助于为患者带来改变生命的药物，”富士胶片生物技术公司总裁兼首席执行官拉尔斯·彼得森表示。“这种更紧密的协调和统一的关注加强了我们与客户的互动和交付方式。”

Together, we offer deep knowledge and experience, speed, flexibility, and scientific rigor—critical elements in bringing complex biologics to life.”.

“我们共同提供深厚的知识和经验、速度、灵活性以及科学的严谨性——这些是将复杂生物制品变为现实的关键要素。”

Alongside FUJIFILM Biosciences and FUJIFILM Biotechnologies, the Fujifilm Life Sciences Group companies also include FUJIFILM Cellular Dynamics, a leading developer and manufacturer of human induced pluripotent stem cells, FUJIFILM Wako Pure Chemical Corporation, and FUJIFILM Toyama Chemical Co., Ltd.

富士胶片生命科学集团的公司还包括FUJIFILM Cellular Dynamics（人类诱导多能干细胞的领先开发商和制造商）、FUJIFILM Wako Pure Chemical Corporation以及FUJIFILM Toyama Chemical Co., Ltd.

To learn more, the Fujifilm Life Sciences Group companies will be at BIO International in Boston from June 16-19, 2025 at Booth 2334 and Booth 2234, for more information, please visit: https://www.fujifilm.com/us/en/lifesciences..

要了解更多信息，富士胶片生命科学集团的公司将于2025年6月16日至19日在波士顿举行的国际生物技术大会（BIO International）上参展，展位号为2334和2234。欲了解更多信息，请访问：https://www.fujifilm.com/us/en/lifesciences。

For more information about FUJIFILM Biosciences, please visit fujifilmbiosciences.fujifilm.com and for more information about FUJIFILM Biotechnologies, please visit fujifilmbiotechnologies.fujifilm.com.

有关富士胶片生物科学的更多信息，请访问 fujifilmbiosciences.fujifilm.com；有关富士胶片生物技术的更多信息，请访问 fujifilmbiotechnologies.fujifilm.com。

*1 Outside the U.S., the distributor will be varied.

*1 在美国以外，经销商会有所不同。

Life Sciences (www.fujifilm.com/us/en/lifesciences)

生命科学 (www.fujifilm.com/us/en/lifesciences)

FUJIFILM Biosciences (fujifilmbiosciences.fujifilm.com)

富士胶片生物科学 (fujifilmbiosciences.fujifilm.com)

FUJIFILM Biotechnologies (fujifilmbiotechnologies.fujifilm.com)

富士胶片生物技术 (fujifilmbiotechnologies.fujifilm.com)

About FUJIFILM Biosciences

关于富士胶片生物科学

With a foundation in cell culture that dates back to 1970, FUJIFILM Biosciences is a global, full spectrum supplier to the life sciences market, providing products and services that assist customers in advancing healthcare initiatives. With an expanding portfolio of applications supported that include life science and discovery research, cell and gene therapy, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers and manufacturers worldwide.

富士胶片生物科学公司自1970年起就奠定了细胞培养的基础，是全球生命科学市场的全方位供应商，提供有助于客户推动医疗保健计划的产品和服务。公司支持的应用领域不断扩大，包括生命科学研究与发现、细胞和基因治疗，以及生物治疗药物和疫苗的大规模生产，因而赢得了全球研究人员和制造商的信任。

For over 50 years, FUJIFILM Biosciences’ Mission has been to empower all who bring medicines and treatments to life with unmatched quality and responsiveness in its products and custom solutions, providing customers with the vital resources needed to enrich human lives through innovative, accessible therapies.

五十多年来，富士胶片生物科学公司的使命一直是通过其产品和定制解决方案，以无与伦比的质量和响应能力，为所有致力于将药物和治疗方案变为现实的人提供支持，为客户提供通过创新且可及的疗法丰富人类生活所需的关键资源。

The Company’s facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth.

公司的设施遵守ISO和FDA的规定，在美国、日本和荷兰的生产设施遵循cGMP指南，并在中国设有培养基优化中心。所有地点都优先采用符合富士胶片2030年可持续价值计划的策略，以实现可持续增长。

FUJIFILM Biosciences is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation. For more information, please visit: fujifilmbiosciences.fujifilm.com.

富士胶片生物科学公司是富士胶片控股美洲公司的子公司，隶属于富士胶片控股公司。欲了解更多信息，请访问：fujifilmbiosciences.fujifilm.com。

Source: fujifilm.com

来源：fujifilm.com